CoChat
Sign Up
Cited by 28

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors

Fuentealba, Rodrigo A., Marasa, Jayne, Diamond, Marc I., Piwnica-Worms, David, Weihl, Conrad C.·2012·Human Molecular Genetics
DOI 10.1093/hmg/ddr500
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddr500

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 95

  1. La Spada, 1991, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, Nature, 352, 77, 10.1038/352077a0 · DOI
  2. Shao, 2007, Polyglutamine diseases: emerging concepts in pathogenesis and therapy, Hum. Mol. Genet., 16, R115, 10.1093/hmg/ddm213 · DOI
  3. Caine, 1983, Psychiatric syndromes in Huntington's disease, Am. J. Psychiatry, 140, 728, 10.1176/ajp.140.6.728 · DOI · Paper page
  4. Walker, 2007, Huntington's disease, Lancet, 369, 218, 10.1016/S0140-6736(07)60111-1 · DOI
  5. MacDonald, 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell, 72, 971, 10.1016/0092-8674(93)90585-E · DOI · Paper page
  6. Stine, 1993, Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15, Hum. Mol. Genet., 2, 1547, 10.1093/hmg/2.10.1547 · DOI
  7. Rubinsztein, 1996, Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats, Am. J. Hum Genet., 59, 16
  8. Scherzinger, 1999, Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology, Proc. Natl Acad. Sci. USA, 96, 4604, 10.1073/pnas.96.8.4604 · DOI
  9. Narain, 1999, A molecular investigation of true dominance in Huntington's disease, J. Med. Genet., 36, 739, 10.1136/jmg.36.10.739 · DOI
  10. Graham, 2006, Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models, Neurobiol. Dis., 21, 444, 10.1016/j.nbd.2005.08.007 · DOI
  11. Colby, 2006, Stochastic kinetics of intracellular huntingtin aggregate formation, Nat. Chem. Biol., 2, 319, 10.1038/nchembio792 · DOI
  12. Chen, 2002, Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation, Proc. Natl Acad. Sci. USA, 99, 11884, 10.1073/pnas.182276099 · DOI
  13. Nagai, 2007, A toxic monomeric conformer of the polyglutamine protein, Nat. Struct. Mol. Biol., 14, 332, 10.1038/nsmb1215 · DOI
  14. Thakur, 2009, Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism, Nat. Struct. Mol. Biol., 16, 380, 10.1038/nsmb.1570 · DOI
  15. Chen, 2002, Amyloid-like features of polyglutamine aggregates and their assembly kinetics, Biochemistry, 41, 7391, 10.1021/bi011772q · DOI
  16. Williams, 2008, Polyglutamine neurodegeneration: protein misfolding revisited, Trends Neurosci., 31, 521, 10.1016/j.tins.2008.07.004 · DOI
  17. Perez, 1998, Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation, J. Cell. Biol., 143, 1457, 10.1083/jcb.143.6.1457 · DOI
  18. Kazantsev, 1999, Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells, Proc. Natl Acad. Sci. USA, 96, 11404, 10.1073/pnas.96.20.11404 · DOI
  19. Chen, 2001, Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity, J. Mol. Biol., 311, 173, 10.1006/jmbi.2001.4850 · DOI
  20. McCampbell, 2000, CREB-binding protein sequestration by expanded polyglutamine, Hum. Mol. Genet., 9, 2197, 10.1093/hmg/9.14.2197 · DOI
  21. Nucifora, 2001, Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity, Science, 291, 2423, 10.1126/science.1056784 · DOI
  22. Steffan, 2000, The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription, Proc. Natl Acad. Sci. USA, 97, 6763, 10.1073/pnas.100110097 · DOI
  23. Huang, 1998, Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins, Somat. Cell Mol. Genet., 24, 217, 10.1023/B:SCAM.0000007124.19463.e5 · DOI
  24. Yamanaka, 2010, Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction, Hum. Mol. Genet., 19, 2099, 10.1093/hmg/ddq087 · DOI
  25. Derkatch, 2004, Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro, Proc. Natl Acad. Sci. USA, 101, 12934, 10.1073/pnas.0404968101 · DOI
  26. Urakov, 2010, Interdependence of amyloid formation in yeast: implications for polyglutamine disorders and biological functions, Prion, 4, 45, 10.4161/pri.4.1.11074 · DOI
  27. DePace, 1998, A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion, Cell, 93, 1241, 10.1016/S0092-8674(00)81467-1 · DOI
  28. Meriin, 2002, Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1, J. Cell Biol., 157, 997, 10.1083/jcb.200112104 · DOI
  29. Osherovich, 2001, Multiple Gln/Asn-rich prion domains confer susceptibility to induction of the yeast [PSI(+)] prion, Cell, 106, 183, 10.1016/S0092-8674(01)00440-8 · DOI
  30. Furukawa, 2009, Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases, J. Neurosci., 29, 5153, 10.1523/JNEUROSCI.0783-09.2009 · DOI
  31. Doi, 2010, The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases, Neurosci. Res., 66, 131, 10.1016/j.neures.2009.10.004 · DOI
  32. Doi, 2008, RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells, J. Biol. Chem., 283, 6489, 10.1074/jbc.M705306200 · DOI
  33. Fuentealba, 2010, Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43, J. Biol. Chem., 285, 26304, 10.1074/jbc.M110.125039 · DOI
  34. Schwab, 2008, Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease, J. Neuropathol. Exp. Neurol., 67, 1159, 10.1097/NEN.0b013e31818e8951 · DOI
  35. Michelitsch, 2000, A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions, Proc. Natl Acad. Sci. USA, 97, 11910, 10.1073/pnas.97.22.11910 · DOI
  36. Takahashi, 2010, Polyglutamine diseases: Where does toxicity come from? What is toxicity? Where are we going?, J. Mol. Cell Biol., 2, 180, 10.1093/jmcb/mjq005 · DOI
  37. Kazantsev, 2002, A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila, Nat. Genet., 30, 367, 10.1038/ng864 · DOI
  38. Pollitt, 2003, A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor, Neuron, 40, 685, 10.1016/S0896-6273(03)00697-4 · DOI · Paper page
  39. Tanaka, 2004, Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease, Nat. Med., 10, 148, 10.1038/nm985 · DOI
  40. Heiser, 2002, Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay, Proc. Natl Acad. Sci. USA, 99, 16400, 10.1073/pnas.182426599 · DOI
  41. Wang, 2005, Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation, BMC Neurosci., 6, 1, 10.1186/1471-2202-6-1 · DOI
  42. Aiken, 2004, A cell-based screen for drugs to treat Huntington's disease, Neurobiol. Dis., 16, 546, 10.1016/j.nbd.2004.04.001 · DOI
  43. Coufal, 2007, Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments, J. Biomol. Screen., 12, 351, 10.1177/1087057107299428 · DOI
  44. Piccioni, 2004, A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor, Hum. Mol. Genet., 13, 437, 10.1093/hmg/ddh045 · DOI
  45. Zhang, 2005, A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo, Proc. Natl Acad. Sci. USA, 102, 892, 10.1073/pnas.0408936102 · DOI
  46. Doumanis, 2009, RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation, PLoS One, 4, e7275, 10.1371/journal.pone.0007275 · DOI
  47. Desai, 2006, Biologically active molecules that reduce polyglutamine aggregation and toxicity, Hum. Mol. Genet., 15, 2114, 10.1093/hmg/ddl135 · DOI
  48. Ashburn, 2004, Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov., 3, 673, 10.1038/nrd1468 · DOI · Paper page
  49. Chong, 2006, A clinical drug library screen identifies astemizole as an antimalarial agent, Nat. Chem. Biol., 2, 415, 10.1038/nchembio806 · DOI
  50. Chong, 2007, New uses for old drugs, Nature, 448, 645, 10.1038/448645a · DOI
  51. Hendrick, 1993, Control of folding and membrane translocation by binding of the chaperone DnaJ to nascent polypeptides, Proc. Natl Acad. Sci. USA, 90, 10216, 10.1073/pnas.90.21.10216 · DOI
  52. Schroder, 1993, DnaK, DnaJ and GrpE form a cellular chaperone machinery capable of repairing heat-induced protein damage, EMBO J., 12, 4137, 10.1002/j.1460-2075.1993.tb06097.x · DOI
  53. Buchberger, 1994, A conserved loop in the ATPase domain of the DnaK chaperone is essential for stable binding of GrpE, Nat. Struct. Biol., 1, 95, 10.1038/nsb0294-95 · DOI
  54. Gross, 2005, Real-time imaging of ligand-induced IKK activation in intact cells and in living mice, Nat. Methods, 2, 607, 10.1038/nmeth779 · DOI
  55. Li, 2007, Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy, J. Biol. Chem., 282, 3157, 10.1074/jbc.M609972200 · DOI
  56. Zhang, 1999, A simple statistical parameter for use in evaluation and validation of high throughput screening assays, J. Biomol. Screen., 4, 67, 10.1177/108705719900400206 · DOI · Paper page
  57. van Bebber, 2010, Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish, Neurobiol. Dis., 39, 265, 10.1016/j.nbd.2010.03.023 · DOI
  58. Wang, 2010, Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation, J. Biol. Chem., 285, 15714, 10.1074/jbc.M109.098806 · DOI
  59. Webb, 2004, Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases, Int. J. Biochem. Cell Biol., 36, 2541, 10.1016/j.biocel.2004.02.003 · DOI
  60. Shimohata, 2002, Expanded polyglutamine stretches form an ‘aggresome, Neurosci. Lett., 323, 215, 10.1016/S0304-3940(02)00162-3 · DOI
  61. Yamamoto, 2006, Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway, J. Cell Biol., 172, 719, 10.1083/jcb.200510065 · DOI
  62. Kalgutkar, 2003, In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes, Drug Metab. Dispos., 31, 1240, 10.1124/dmd.31.10.1240 · DOI
  63. Korn, 2001, Suppression of experimental autoimmune neuritis by leflunomide, Brain, 124, 1791, 10.1093/brain/124.9.1791 · DOI
  64. Gold, 2011, Pathophysiology of multiple sclerosis and the place of teriflunomide, Acta Neurol. Scand., 124, 75, 10.1111/j.1600-0404.2010.01444.x · DOI
  65. O'Connor, 2006, A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses, Neurology, 66, 894, 10.1212/01.wnl.0000203121.04509.31 · DOI
  66. Davis, 1996, The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase, Biochemistry, 35, 1270, 10.1021/bi952168g · DOI
  67. Greene, 1995, Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide, Biochem. Pharmacol., 50, 861, 10.1016/0006-2952(95)00255-X · DOI
  68. Liu, 2000, Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents, Structure, 8, 25, 10.1016/S0969-2126(00)00077-0 · DOI
  69. Williamson, 1995, Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound, J. Biol. Chem., 270, 22467, 10.1074/jbc.270.38.22467 · DOI
  70. Cherwinski, 1995, The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis, J. Pharmacol. Exp. Ther., 275, 1043, 10.1016/S0022-3565(25)12093-4 · DOI
  71. Bruneau, 1998, Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide, Biochem. J., 336, 299, 10.1042/bj3360299 · DOI
  72. Christopherson, 2002, Inhibitors of de novo nucleotide biosynthesis as drugs, Acc. Chem. Res., 35, 961, 10.1021/ar0000509 · DOI
  73. Knecht, 2000, Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid, Chem. Biol. Interact., 124, 61, 10.1016/S0009-2797(99)00144-1 · DOI
  74. Ju, 2008, Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease, J. Biol. Chem., 283, 30289, 10.1074/jbc.M805517200 · DOI
  75. Tamguney, 2009, Measuring prions by bioluminescence imaging, Proc. Natl Acad. Sci. USA, 106, 15002, 10.1073/pnas.0907339106 · DOI
  76. Watts, 2011, Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease, Proc. Natl Acad. Sci. USA, 108, 2528, 10.1073/pnas.1019034108 · DOI · Paper page
  77. Hashimoto, 2011, Characterization of oligomer formation of amyloid-{beta} peptide using a split-luciferase complementation assay, J. Biol. Chem., 286, 27081, 10.1074/jbc.M111.257378 · DOI
  78. O'Leary, 2010, Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden, Mol. Neurodegener., 5, 45, 10.1186/1750-1326-5-45 · DOI
  79. Taniguchi, 2005, Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins, J. Biol. Chem., 280, 7614, 10.1074/jbc.M408714200 · DOI
  80. Medina, 2011, Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity, Brain Pathol., 21, 140, 10.1111/j.1750-3639.2010.00430.x · DOI
  81. Necula, 2007, Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization, Biochemistry, 46, 8850, 10.1021/bi700411k · DOI · Paper page
  82. Yamashita, 2009, Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models, FEBS Lett., 583, 2419, 10.1016/j.febslet.2009.06.042 · DOI
  83. Xu, 1995, Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide, J. Biol. Chem., 270, 12398, 10.1074/jbc.270.21.12398 · DOI
  84. Manna, 1999, Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression, J. Immunol., 162, 2095, 10.4049/jimmunol.162.4.2095 · DOI
  85. Latchoumycandane, 2006, Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes, Toxicol. Appl. Pharmacol., 217, 125, 10.1016/j.taap.2006.08.001 · DOI
  86. Latchoumycandane, 2007, Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury, Hepatology, 45, 412, 10.1002/hep.21475 · DOI
  87. Sawamukai, 2007, Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells, J. Immunol., 179, 6479, 10.4049/jimmunol.179.10.6479 · DOI
  88. Apostol, 2006, Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity, Hum. Mol. Genet., 15, 273, 10.1093/hmg/ddi443 · DOI
  89. Scappini, 2007, Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase, Hum. Mol. Genet., 16, 1862, 10.1093/hmg/ddm134 · DOI
  90. Frost, 2009, The expanding realm of prion phenomena in neurodegenerative disease, Prion, 3, 74, 10.4161/pri.3.2.8754 · DOI
  91. Crook, 2011, Huntington's disease: can mice lead the way to treatment, Neuron, 69, 423, 10.1016/j.neuron.2010.12.035 · DOI
  92. Korn, 2004, Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide—mechanisms independent of pyrimidine depletion, J. Leukoc. Biol., 76, 950, 10.1189/jlb.0504308 · DOI
  93. Merrill, 2009, Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis, J. Neurol., 256, 89, 10.1007/s00415-009-0075-3 · DOI
  94. Palmer, 2010, Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis, Curr. Opin. Investig. Drugs, 11, 1313
  95. Shao, 2008, Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation, Mol. Cell. Biol., 28, 5196, 10.1128/MCB.00079-08 · DOI · Paper page

Cited by

Sorted by citations

See all 28

Metadata

Authors
Fuentealba, R. A., Marasa, J., Diamond, M. I., Piwnica-Worms, D., & Weihl, C. C.
Venue
Human Molecular Genetics
Publisher
Oxford University Press (OUP)
Published
2011-11-03
Volume
21
Issue
3
Pages
664-680
ISSN
  • 1460-2083
  • 0964-6906
DOI
10.1093/hmg/ddr500
Cited by
28
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review